Evaluation of the Safety and Effectiveness of Intradermal Administration of QR678 Neo Hair Growth Factor Formulation: A Phase-IV, Open-Label, Single-Arm Multi-Ethnicity Clinical Trial
January 2022
in “
Journal of Cosmetic Dermatology
”
Studysummary This study found that intradermal administration of QR678 Neo® significantly reduced hair fall and improved hair growth in patients with androgenetic alopecia and female pattern hair loss, with no side effects reported during long-term follow-up.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on onlinelibrary.wiley.com →